<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36510">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631226</url>
  </required_header>
  <id_info>
    <org_study_id>CSPTneonat_2015_01</org_study_id>
    <nct_id>NCT02631226</nct_id>
  </id_info>
  <brief_title>Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.</brief_title>
  <acronym>EME</acronym>
  <official_title>Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted in the Hospital: a Multicenter Study (EME Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prevalence and risk factors for
      multi-resistant enterobacteriaceae colonization in less than 32 weeks pregnant women
      admitted to the hospital and its transmission to the newborn, in order to avoid neonatal
      intensive care unit spread and nosocomial outbreaks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of multi-resistant enterobacteriaceae colonisation in less than 32 weeks pregnant women</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of multi-resistant enterobacteriaceae colonisation of African or Asian pregnant women</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of multi-resistant enterobacteriaceae colonisation of pregnant women admitted to the hospital by preterm premature rupture of membranes (PPROM)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmission rate from the colonized woman to the newborn</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of multi-resisitant enterobacteriacea sepsis in the Neonatal Unit</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Multi-resistant Enterobacteriaceae Colonisation</condition>
  <condition>Pregnancy</condition>
  <condition>Nosocomial Outbreaks</condition>
  <arm_group>
    <arm_group_label>Pregnant women colonized by resistant enterobacteria</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Less than 32 weeks pregnant woman admitted to the hospital and her newborn if the mother
        is a multi-resistant enterobacteriaceae carrier.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less than 32 weeks pregnant woman

          -  Admitted to the hospital

        Exclusion Criteria:

          -  Screening done after 48 hours of admission

          -  When delivery occurs before screening is performed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victoria Aldecoa-Bilbao, M.D.</last_name>
    <phone>0034937231010</phone>
    <phone_ext>29314</phone_ext>
    <email>valdecoa@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Sabadell. Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Aldecoa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 10, 2016</lastchanged_date>
  <firstreceived_date>November 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Victoria Aldecoa-Bilbao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
